A Phase 3 interventional study of Trastuzumab deruxtecan (DS-8201a) and Capecitabine in Breast Cancer, sponsored by Daiichi Sankyo. Completed at 208 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.
Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 6th largest by enrollment, is one of 6 that started in 2018, is one of 12 in phase 3, and was the 8th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
SOLTI Breast Cancer Research Group · Sites in France, Germany, Spain
Ages 18+
Kristina A. Fanucci · Sites in United States
Ages 18+
Institut Claudius Regaud · Sites in France
Ages 18+
By country, each count listing its studies:
trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab deruxtecan is the treatment under test here. Read study by study →
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 37 · Phase 3 12 · Phase 4 2
First in 2017; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 557 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 139 across the 58 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 58 have an industry lead sponsor. The 10 most frequent:
Daiichi Sankyo is the lead sponsor of 322 studies on the registry; 37 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 38 (75%) have results posted.
24 studies in Breast Neoplasms by Daiichi Sankyo: 6 open now, 8 under way, 3 of them phase 3. Of 16 finished, 8 (50%) have results posted.
Among the 24 studies in Breast Neoplasms by Daiichi Sankyo, this one is the 4th largest by enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2018, is one of 6 in phase 3, and was the 10th registered.
Daiichi Sankyo’s Breast Neoplasms studies by the year they started, since 1999.
13 of the studies testing trastuzumab deruxtecan in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05950945Phase 3Daiichi SankyoTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | 2027-10-01 |
| NCT06048718MedSIRT-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases | 2026-11 |
| NCT04553770Jonsson Comprehensive Cancer CenterTrastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | 2026-12-31 |
| NCT06486883MedSIRSafety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype | 2027-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, from their registry updates:
Among Daiichi Sankyo’s 24 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will compare DS-8201a to physician choice standard treatment.
Participants must have HER2-low breast cancer that has been treated before.
Participants' cancer:
This is a randomized, 2-arm, Phase 3, open-label, multicenter study to compare the safety and efficacy of trastuzumab deruxtecan versus the physician's choice (2:1) in HER2-low, unresectable and/or metastatic breast cancer participants.
The Sponsor proposes to define a new HER2-low population in this trial including tumors with IHC 1+ and IHC 2+/ISH- HER2 expression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has documented breast cancer that:
Has adequate available or is wiling to provide fresh biopsies prior to randomization for:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to DS8201a
Drug: Trastuzumab deruxtecan (DS-8201a)
HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to Physician's choice from the following options: * Capecitabine * Eribulin * Gemcitabine * Paclitaxel * Nab-paclitaxel
Drug: Capecitabine · Drug: Eribulin · Drug: Gemcitabine · Drug: Paclitaxel · Drug: Nab-paclitaxel
DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously
Also known as: DS-8201a
Administered according to label, as one option for Physician's Choice (determined before randomization)
Administered according to label, as one option for Physician's Choice (determined before randomization)
Administered according to label, as one option for Physician's Choice (determined before randomization)
Administered according to label, as one option for Physician's Choice (determined before randomization)
Administered according to label, as one option for Physician's Choice (determined before randomization)
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.
Time frame: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-low Breast Cancer (All Patients) Regardless of Hormone Receptor Status
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.
Time frame: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Progression-free Survival Based on Investigator Assessment in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.
Time frame: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Progression-free Survival Based on Investigator Assessment in Participants With HER2-low Breast Cancer (All Patients)
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.
Time frame: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Overall Survival (OS) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive.
Time frame: From the date of randomization up to the date of death due to any cause, up to approximately 3 years
Number of Overall Survival Events (Deaths)
Time frame: From the date of randomization up to the date of death due to any cause, up to approximately 3 years
Overall Survival (OS) in All Patients
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive.
Time frame: From the date of randomization up to the date of death due to any cause, up to approximately 3 years
Best Overall Response and Confirmed Objective Response Rate (ORR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment.
Time frame: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
Best Overall Response and Confirmed Objective Response Rate (ORR) in Participants With HER2-low Breast Cancer (All Patients)
Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment.
Time frame: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
Duration of Response in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
Duration of Response (DoR) is defined as the date of the first documented objective response (complete response \[CR\] or partial response \[PR\]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method.
Time frame: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
Duration of Response in Participants With HER2-low Breast Cancer (All Patients)
Duration of Response (DoR) is defined as the date of the first documented objective response (complete response \[CR\] or partial response \[PR\]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method.
Time frame: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
All-Cause Mortality
All-cause mortality is defined as all anticipated and unanticipated deaths due to any cause, with the number and frequency of such events by arm or comparison group of the clinical study.
Time frame: From the date of randomization up to the date of death due to any cause, up to approximately 3 years
A total of 557 participants were enrolled and randomized to treatment at 161 study sites in the United States (27 study sites), Japan (18 sites), France (16 sites), China (15 sites), Italy (13 sites), Spain (12 sites), Greece (8 sites), Portugal (8 sites), Republic of Korea (8 sites), Israel (6 sites), Switzerland (6 sites), Austria (4 sites), Belgium (4 sites), Russia (3 sites), Sweden (3 sites), Taiwan (3 sites), Unted Kingdom (3 sites), Canada (2 sites), and Hungary (2 sites).
| Milestone | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice |
|---|---|---|
| Started | 373 | 184 |
| Full analysis set (all randomized patients) | 373 | 184 |
| Safety analysis set (all randomized patients who received at least 1 dose of study treatment) | 371 | 172 |
| Completed | 58 | 3 |
| Not completed | 315 | 181 |
| Withdrew: Progressive disease as per recist v1.1 | 220 | 130 |
| Withdrew: Adverse event | 60 | 14 |
| Withdrew: Withdrawal by subject | 12 | 11 |
| Withdrew: Clinical progression by investigator | 10 | 8 |
| Withdrew: Death | 5 | 2 |
| Withdrew: Physician decision | 4 | 3 |
| Withdrew: Other | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Randomized, but not treated | 2 | 12 |
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.
| months | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice |
|---|---|---|
| Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer | 10.1 (9.5 to 11.5) | 5.4 (4.4 to 7.1) |
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.
| months | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice |
|---|---|---|
| Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-low Breast Cancer (All Patients) Regardless of Hormone Receptor Status | 9.9 (9.0 to 11.3) | 5.1 (4.2 to 6.8) |
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.
| months | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice |
|---|---|---|
| Progression-free Survival Based on Investigator Assessment in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer | 9.6 (8.4 to 10.0) | 4.2 (3.4 to 4.9) |
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.
| months | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice |
|---|---|---|
| Progression-free Survival Based on Investigator Assessment in Participants With HER2-low Breast Cancer (All Patients) | 8.8 (8.3 to 9.8) | 4.2 (3.0 to 4.5) |
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive.
| months | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice |
|---|---|---|
| Overall Survival (OS) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer | 23.9 (20.8 to 24.8) | 17.5 (15.2 to 22.4) |
| events (deaths) | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice |
|---|---|---|
| Number of Overall Survival Events (Deaths) | 149 | 90 |
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive.
| months | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice |
|---|---|---|
| Overall Survival (OS) in All Patients | 23.4 (20.0 to 24.8) | 16.8 (14.5 to 20.0) |
Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment.
| Participants | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice |
|---|---|---|
| BICR: Complete response | 12 | 1 |
| BICR: Partial response | 164 | 26 |
| BICR: Stable disease | 115 | 81 |
| BICR: Progressive disease | 26 | 34 |
| BICR: Not evaluable | 14 | 21 |
| Investigator: Complete response | 5 | 0 |
| Investigator: Partial response | 163 | 30 |
| Investigator: Stable disease | 124 | 80 |
| Investigator: Progressive disease | 28 | 34 |
| Investigator: Not evaluable | 11 | 19 |
| BICR: Confirmed Objective response rate | 175 | 27 |
| Investigator: Confirmed Objective response rate | 168 | 30 |
Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment.
| Participants | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice |
|---|---|---|
| BICR: Complete response | 13 | 2 |
| BICR: Partial response | 183 | 28 |
| BICR: Stable disease | 129 | 91 |
| BICR: Progressive disease | 31 | 41 |
| BICR: Not evaluable | 17 | 22 |
| Investigator: Complete response | 6 | 0 |
| Investigator: Partial response | 187 | 31 |
| Investigator: Stable disease | 135 | 93 |
| Investigator: Progressive disease | 32 | 40 |
| Investigator: Not evaluable | 13 | 20 |
| BICR: Confirmed Objective response rate | 195 | 30 |
| Investigator: Confirmed Objective response rate | 193 | 31 |
Duration of Response (DoR) is defined as the date of the first documented objective response (complete response \[CR\] or partial response \[PR\]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method.
| months | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice |
|---|---|---|
| BICR: DoR | 10.7 (8.5 to 13.7) | 6.8 (6.5 to 9.9) |
| Investigator: DoR | 8.3 (7.1 to 11.1) | 5.6 (3.6 to 6.8) |
Duration of Response (DoR) is defined as the date of the first documented objective response (complete response \[CR\] or partial response \[PR\]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method.
| months | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice |
|---|---|---|
| BICR: DoR | 10.7 (8.5 to 13.2) | 6.8 (6.0 to 9.9) |
| Investigator: DoR | 8.3 (7.0 to 9.9) | 5.6 (3.7 to 6.6) |
All-cause mortality is defined as all anticipated and unanticipated deaths due to any cause, with the number and frequency of such events by arm or comparison group of the clinical study.
| Participants | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice |
|---|---|---|
| All-Cause Mortality | 148 | 88 |
Collected over Adverse events (AEs) were collected from the time of signing the main informed consent form up to 40 days (+7 days) after the last treatment, whether observed by the investigator or reported by the participant, up to approximately 3 years in the Safety Analysis Set.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trastuzumab Deruxtecan (T-DXd) | 149/373 (39.9%) | 103/371 (27.8%) | 366/371 (98.7%) |
| Physician's Choice | 90/184 (48.9%) | 43/172 (25%) | 167/172 (97.1%) |
| Event | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice |
|---|---|---|
| OverdoseInjury, poisoning and procedural complications | 0/371 | 5/172 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/371 | 4/172 |
| PneumoniaInfections and infestations | 7/371 | 1/172 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 7/371 | 0/172 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 7/371 | 0/172 |
| Medication errorInjury, poisoning and procedural complications | 0/371 | 3/172 |
| SepsisInfections and infestations | 5/371 | 0/172 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/371 | 2/172 |
| NeutropeniaBlood and lymphatic system disorders | 0/371 | 2/172 |
| ColitisGastrointestinal disorders | 0/371 | 2/172 |
| Event | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice |
|---|---|---|
| NauseaGastrointestinal disorders | 281/371 | 52/172 |
| VomitingGastrointestinal disorders | 148/371 | 23/172 |
| AlopeciaSkin and subcutaneous tissue disorders | 147/371 | 57/172 |
| AnaemiaBlood and lymphatic system disorders | 137/371 | 44/172 |
| Neutrophil count decreasedInvestigations | 81/371 | 61/172 |
| ConstipationGastrointestinal disorders | 124/371 | 38/172 |
| Decreased appetiteMetabolism and nutrition disorders | 118/371 | 33/172 |
| FatigueGeneral disorders | 110/371 | 49/172 |
| White blood cell count decreasedInvestigations | 78/371 | 49/172 |
| DiarrhoeaGastrointestinal disorders | 100/371 | 38/172 |
Baseline characteristics were assessed in the Full Analysis Set. The Full Analysis Set included all participants randomized into the study, including those who did not receive a dose of study treatment. Participants were analyzed according to the treatments and strata assigned at randomization.
| Age, Categorical(Participants) | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 290 | 136 | 426 |
| >=65 years | 83 | 48 | 131 |
| Age, Continuous(years) | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice | Total |
|---|---|---|---|
| Mean | 56.5 ± 10.6 | 56.5 ± 11.5 | 56.5 ± 10.9 |
| Sex: Female, Male(Participants) | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice | Total |
|---|---|---|---|
| Female | 371 | 184 | 555 |
| Male | 2 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Trastuzumab Deruxtecan (T-DXd) | Physician's Choice | Total |
|---|---|---|---|
| White | 176 | 91 | 267 |
| Black or African American | 7 | 3 | 10 |
| Asian | 151 | 72 | 223 |
| Native Hawaiian or other Pacific Islander | 1 | 0 | 1 |
| Other | 38 | 17 | 55 |
| Missing | 0 | 1 | 1 |
Showing the first 100 of 208 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Data sharing details ↗ · vivli.org
Ran from Dec 2018 to primary completion in Jan 2022, 36 months.
Results were first posted in Jun 2023, 1 year 5 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 36 months is close to that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → May 2026, on Sep 28, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab deruxtecan